Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kineta (KA) has shared an update.
Kineta, Inc. has shared exciting news in their latest press release about the progress of their VISTA-101 Phase 1/2 clinical trial. Their innovative immunotherapy treatment, KVA12123, is currently being tested on patients with advanced solid tumors. This update marks a significant milestone for the company and holds potential implications for the future of cancer treatment.
See more data about KA stock on TipRanks’ Stock Analysis page.
